Transdifferentiation of B‐lymphoblastic leukemia to histiocytic sarcoma after immunotherapy
American Journal of Hematology · 2023
DOI: 10.1002/ajh.26983 ↗Kurz gefasst
Leserbrief in der Zeitschrift American Journal of Hematology, 2023. Verfasst von Elena M Fenu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Histiocytic Sarcoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, B-Cell. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 8 Literaturangaben. Gefördert von: CURE Childhood Cancer.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Division of Hematopathology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Vinodh Pillai
Förderung
- CURE Childhood Cancer
Zitieren
APA
Fenu, E. M., Margolskee, E., & Pillai, V. (2023). Transdifferentiation of B‐lymphoblastic leukemia to histiocytic sarcoma after immunotherapy. American Journal of Hematology. https://doi.org/10.1002/ajh.26983
Vancouver
Fenu EM, Margolskee E, Pillai V. Transdifferentiation of B‐lymphoblastic leukemia to histiocytic sarcoma after immunotherapy. American Journal of Hematology. 2023. doi:10.1002/ajh.26983
BibTeX
@article{Fenu2023,
author = {Fenu, Elena M and Margolskee, Elizabeth and Pillai, Vinodh},
title = {Transdifferentiation of B‐lymphoblastic leukemia to histiocytic sarcoma after immunotherapy},
journal = {American Journal of Hematology},
year = {2023},
doi = {10.1002/ajh.26983}
}
EUVIMED